Wearable TOMAC Therapy Cuts Restless Legs Severity by 8 Points in 90 Days
A 232-patient real-world study finds tonic motor activation therapy significantly reduces RLS symptoms and improves sleep quality.
Summary
Restless legs syndrome affects millions and often becomes resistant to standard medications. The THRIVE study followed 232 adults with moderate-to-severe refractory RLS who used the Nidra wearable device, which delivers tonic motor activation (TOMAC) therapy — gentle electrical stimulation to leg muscles during the night. After 90 days, patients showed meaningful reductions in RLS symptom severity scores and improved sleep quality. Nearly two-thirds of patients were rated as clinically improved by their physicians. Importantly, more patients were able to reduce their RLS medications than needed to increase them, suggesting TOMAC may help lower reliance on drugs that often carry side effects. No serious device-related adverse events occurred, supporting its safety profile for this difficult-to-treat population.
Detailed Summary
Restless legs syndrome is a neurological condition causing irresistible urges to move the legs, typically worsening at night and severely disrupting sleep. Many patients eventually develop refractory RLS — meaning standard dopaminergic medications no longer provide adequate relief or cause augmentation, a paradoxical worsening. This creates an urgent need for non-pharmacological alternatives.
The THRIVE study is a multicenter, prospective, real-world observational trial enrolling 325 patients prescribed the Nidra device, a wearable that delivers tonic motor activation (TOMAC) therapy. TOMAC works by applying mild electrical stimulation to activate leg muscles in a sustained, non-painful pattern, thought to suppress the abnormal sensory signaling driving RLS symptoms. The indicated intent-to-treat analysis focused on 232 adults with moderate-to-severe refractory RLS.
After 90 days of treatment, the primary endpoint — change in the International RLS Study Group (IRLS) score — improved by an average of 8.4 points. A reduction of this magnitude is generally considered clinically meaningful. Sleep quality, measured by the MOS Sleep Problems Index II, improved by 12.8 points. Sixty-four percent of patients were rated as clinically improved by their clinicians, and the mean clinician global impression score reflected "much improved" status.
Perhaps most practically significant, patients were nearly twice as likely to reduce their RLS medications as to increase them (19% vs. 11%), and those who reduced medications maintained strong symptom improvement. No serious or severe device-related adverse events were reported.
These findings suggest TOMAC therapy is a viable, safe adjunct or potential substitute for pharmacotherapy in refractory RLS patients. For clinicians managing patients with augmentation or medication side effects, this real-world evidence is encouraging. However, the observational design, absence of a control group, and 90-day follow-up limit causal conclusions and long-term assessment.
Key Findings
- IRLS severity score dropped by 8.4 points at 90 days, a clinically meaningful reduction.
- 64% of patients met clinician-rated responder criteria for meaningful improvement.
- Sleep quality scores improved by 12.8 points on the MOS Sleep Problems Index II.
- 19% of patients reduced RLS medications vs. only 11% who increased them.
- No serious or severe device-related adverse events were recorded across 232 patients.
Methodology
THRIVE is a multicenter, prospective, observational post-market study enrolling 325 patients prescribed TOMAC therapy in real-world clinical settings. The indicated intent-to-treat population of 232 adults had moderate-to-severe refractory RLS, with outcomes assessed at 90 days using validated scales (IRLS, CGI-I, MOS-II). As an observational study, there was no randomized control group.
Study Limitations
This is an observational study without a control or placebo arm, making it impossible to rule out placebo effect or regression to the mean. The summary is based on the abstract only, limiting full assessment of methodology, dropout rates, and adverse event details. The 90-day timeframe does not address long-term efficacy or durability of effect.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.